Enable Accessibility Enable Accessibility

FY2020 Sustainability Highlights

Highlights

icon-RevenueGrowth.jpg

2.2% UNDERLYING REVENUE GROWTH1

REVENUE: Yearly revenue growth was largely driven by our 14 global brands, with underlying revenue growth of 2.2% in FY2020

icon-RevenueGrowth.jpg

11 NEW MOLECULAR ENTITIES

PIPELINE: We are progressing 11 new molecular entities with the potential for up to 15 launches through FY2024

icon-RevenueGrowth.jpg

54 COUNTRIES & TERRITORIES

ACCESS: Our Access to Medicines programs operate in 54 countries and territories around the world and have provided treatment to more than 70,000 patients2

icon-RevenueGrowth.jpg

41,000 THIRDPARTY SUPPLIERS

SUPPLY: We partner with 41,000 third-party suppliers around the world for the materials and services needed for the production and distribution of our medicines

icon-RevenueGrowth.jpg

GLOBAL TOP EMPLOYER CERTIFIED

TOP EMPLOYER: Takeda is one of only 16 companies to achieve Global Top Employer certification for 2021, the fourth year in a row

icon-RevenueGrowth.jpg

52% WOMEN

DIVERSITY, EQUITY AND INCLUSION: Our global organization today comprises 52% women and in our manager population, 40% are women

icon-RevenueGrowth.jpg

CARBON NEUTRAL

CARBON NEUTRALITY: Takeda became carbon neutral across our value chain – a significant first step to reducing company-wide emissions to zero by 2040

icon-RevenueGrowth.jpg

COMMITMENT TO PHILANTHROPY

GLOBAL CSR PROGRAM: We have committed 12.3 billion yen in total since 2016 to corporate philanthropy

  1. Takeda uses certain non-IFRS measures to supplement the analysis of results of operations under International Financial Reporting Standards (“IFRS”). Please refer to appendix pages for definitions, explanations and reconciliations of non-IFRS measures.
  2. From March 2019 - December 2020.